Company news

Oculis Holding AG news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Oculis Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema

December 17, 2023

Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Disease

December 6, 2023

Oculis Reports Q3 2023 Financial Results and Provides Company Update

November 14, 2023

Oculis to Present at Upcoming November Investor Conferences

November 7, 2023

Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema

October 31, 2023

Positive Phase 3 Stage 1 DIAMOND Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress

October 9, 2023

Oculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema

October 4, 2023

Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase

September 10, 2023

Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update

August 28, 2023

OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery

August 7, 2023

First Patient Enrolled in LEOPARD, an Investigator-Initiated Trial, with OCS-01 Eye Drops for the Treatment of Cystoid Macular Edema

August 1, 2023

Oculis Announces to Present at Upcoming August Investor Conferences

July 25, 2023

Oculis to Present at OIS Retina Innovation Summit

July 18, 2023

Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023

June 25, 2023

Oculis Announces Partial Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares

June 12, 2023

Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics

June 11, 2023

Oculis to Participate in Jefferies Healthcare Conference

May 31, 2023

Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares

May 30, 2023

Oculis Announces Launch of Proposed Public Offering of Ordinary Shares

May 29, 2023

Oculis to Participate and Present at Upcoming EuDES Meeting

May 23, 2023

Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops

May 21, 2023

Oculis Co-founders Selected as Finalists in European Inventor Award 2023

May 10, 2023

Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs

April 25, 2023

Oculis to Participate at Upcoming Investor Conferences

April 4, 2023

Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones

April 3, 2023

Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing

March 21, 2023

Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial

March 15, 2023

← Newer news releases

Decks

The 5 newest of 15 decks. Every deck is listed under its year.